Perry F. Renshaw,
MD, PhD, MBA
Languages Spoken: English
Perry Renshaw, MD, PhD, MBA, is a graduate of the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA. He also completed his PhD in Biophysics at the University of Pennsylvania and his MBA at the McCallum Graduate School of Business, Bentley College, in Waltham, MA. Dr. Renshaw serves as the Medical Director of the VISN 19 Mental Illness Research, Education and Clinical Center (MIRECC) at the Salt Lake City Veterans Affairs Medical Center. His training as a biophysicist and psychiatrist has led to a primary research interest in the use of multinuclear magnetic resonance spectroscopy (MRS) neuroimaging to identify changes in brain chemistry associated with psychiatric disorders and substance abuse. Over the past 20 years, he has conducted more than 1,000 MRS brain scans of individuals with mood disorders, with the goal of characterizing the cross-sectional and longitudinal alterations in brain chemistry associated with mood disorders and their treatment. As Professor in the Department of Psychiatry, he has a notable publication record having served as an author on more than 300 publications. His research projects have been funded by the NIH for 18 years, including a NIDA K05 and a collaborative R01 grant.
Specialties
Board Certification and Academic Information
| Academic Departments | Psychiatry
-
Professor |
| Academic Divisions | Adult Psychiatry |
| Board Certification | American Board of Psychiatry & Neurology (Psychiatry) |
Perry Renshaw, MD, PhD, MBA, is a graduate of the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA. He also completed his PhD in Biophysics at the University of Pennsylvania and his MBA at the McCallum Graduate School of Business, Bentley College, in Waltham, MA. Dr. Renshaw serves as the Medical Director of the VISN 19 Mental Illness Research, Education and Clinical Center (MIRECC) at the Salt Lake City Veterans Affairs Medical Center. His training as a biophysicist and psychiatrist has led to a primary research interest in the use of multinuclear magnetic resonance spectroscopy (MRS) neuroimaging to identify changes in brain chemistry associated with psychiatric disorders and substance abuse. Over the past 20 years, he has conducted more than 1,000 MRS brain scans of individuals with mood disorders, with the goal of characterizing the cross-sectional and longitudinal alterations in brain chemistry associated with mood disorders and their treatment. As Professor in the Department of Psychiatry, he has a notable publication record having served as an author on more than 300 publications. His research projects have been funded by the NIH for 18 years, including a NIDA K05 and a collaborative R01 grant.
Academic Locations
801-587-1216
Board Certification and Academic Information
| Academic Departments | Psychiatry
-
Professor |
| Academic Divisions | Adult Psychiatry |
| Board Certification | American Board of Psychiatry & Neurology (Psychiatry) |
Education History
| Graduate Training | Bentley University Business Administration M.B.A. |
| Fellowship | Massachusetts General Hospital Neuroscience Fellow |
| Residency | Massachusetts General Hospital Psychiatry Resident |
| Internship | Brigham and Women's Hospital Internal Medicine Intern |
| Postdoctoral Fellowship | University of Pennsylvania Metabolic NMR Postdoctoral Fellow |
| Professional Medical | University of Pennsylvania Medicine M.D. |
| Doctoral Training | University of Pennsylvania Biophysics Ph.D. |
| Undergraduate | Massachusetts Institute of Technology Chemistry S.B. |
Selected Publications - Journal Articles
Journal Article
- Son YD, Han DH, Kim SM, Min KJ, Renshaw PF (2017). A functional connectivity comparison between attention deficit hyperactivity disorder and bipolar disorder in medication-naive adolescents with mood fluctuation and attention problems. Psychiatr Res Neuroimaging, 263, 1-7.
- Harper DG, Jensen JE, Ravichandran C, Perlis RH, Fava M, Renshaw PF, Iosifescu DV (2017). Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression. Neuropharmacology, 42, 876-885.
- Kang KD, Han DH, Kim SM, Bae S, Renshaw PF (2016). The correlation between cognitive and movement shifting and brain activity in children with ADHD. J Atten Disord, 1-10.
- Kim JE, Kim GH, Hwang J, Kim JY, Renshaw PF, Yurgelun-Todd DA, Kim B, Kang I, Jeon S, Ma J, Lyoo IK, Yoon S (2016). Metabolic alterations in the anterior cingulate cortex and related cognitive deficits in late adolescent methamphetamine users. Addict Biol.
- Harper DG, Jensen JE, Ravichandran C, Perlis RH, Fava M, Renshaw PF, Iosifescu DV (2016). Tissue-type-specific bioenergetics abnormalities in adults with major depression. Neuropsychopharmacology, 42(4), 876-885.
- Yoon S, Kim JE, Hwang J, Kim TS, Kang HJ, Namgung E, Ban S, Oh S, Yang J, Renshaw PF, Lyoo IK (2016). Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder. Biol Psychiatry, 80(6), 439-47.
- Aydin B, Yurt A, Gkmen N, Renshaw P, Olson D, Yildiz A (2016). Trait-related alterations of N-acetylaspartate in euthymic bipolar patients: A longitudinal proton magnetic resonance spectroscopy study. J Affect Disord, 206, 315-320.
- Bae S, Han DH, Kim SM, Shi X, Renshaw PF (2016). Neurochemical correlates of internet game play in adolescents with attention deficit hyperactivity disorder: A proton magnetic resonance spectroscopy (MRS) study. Psychiatry Res, 254, 10-7.
- Kondo DG, Forrest LN, Shi X, Sung YH, Hellem TL, Huber RS, Renshaw PF (08/01/2016). Creatine target engagement with brain bioenergetics: A dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression. Amino Acids, 48(8), 1941-54.
- Jeong BS, Han DH, Kim SM, Lee SW, Renshaw PF (2016). White matter connectivity and Internet gaming disorder. Addict Biol, 21(3), 732-42.
- Han DH, Kim SM, Bae S, Renshaw PF, Anderson JS (2016). A failure of suppression within the default mode network in depressed adolescents with compulsive internet game play. J Affect Disord, 194, 57-64.
- Chung US, Han DH, Shin YJ, Renshaw PF (2016). A prosocial online game for social cognition training in adolescents with high-functioning autism: an fMRI study. Neuropsychiatric Disease and Treatment, 12, 651-60.
- Prisciandaro JJ, Schacht JP, Prescot AP, Renshaw PF, Brown TR, Anton RF (2016). Associations Between Recent Heavy Drinking and Dorsal Anterior Cingulate N-Acetylaspartate and Glutamate Concentrations in Non-Treatment-Seeking Individuals with Alcohol Dependence. Alcohol Clin Exp Res, 40(3), 491-6.
- Yildiz A, Aydin B, Gkmen N, Yurt A, Cohen B, Keskinoglu P, ngr D, Renshaw P (2016). Antimanic Treatment With Tamoxifen Affects Brain Chemistry: A Double-Blind, Placebo-Controlled Proton Magnetic Resonance Spectroscopy Study. Biol Psychiatry Cogn Neurosci Neuroimaging, 1(2), 125-131.
Patent
- Yurgelun-Todd, Deborah, Renshaw, Perry (2019). Methods and compositions for improving cognitive performance 20100041621.
- Renshaw, Perry, Yurgelun-Todd, Deborah (2019). Methods for improving frontal brain bioenergetic metabolism 20100041620.
- Renshaw P, Yurgelun-Todd D (2019). Combination of Creatine, an Omega-3 Fatty Acid, and Citicoline. U.S. Patent No. PCT/US2015/014856. Washington, D.C.:U.S. Patent and Trademark Office.
- Rohan ML, Renshaw PF, Parrow A (2014). Magnetic field treatment techniques. U.S. Patent No. 8,702,582. Washington, D.C.:U.S. Patent and Trademark Office.
- Renshaw PF (2014). Predicting efficacy of psychiatric treatment. U.S. Patent No. 8,694,073. Washington, D.C.:U.S. Patent and Trademark Office.
- Renshaw PF (2013). Compounds for the treatment of psychiatric of substance abuse disorders. U.S. Patent No. 8,575,219. Washington, D.C.:U.S. Patent and Trademark Office.
- Yurgelun-Todd DA, Renshaw PF (2013). Use of secretin in treatments of disorders associated with amygdala. U.S. Patent No. 8,524,655. Washington, D.C.:U.S. Patent and Trademark Office.
- Rohan ML, Renshaw PF, Parrow A (2012). Magentc field treatment techniques. U.S. Patent No. 8,303,480. Washington, D.C.:U.S. Patent and Trademark Office.
- Renshaw PF (2011). Compounds for the treatment of psychiatric substance abuse disorders. U.S. Patent No. 7,863,254. Washington, D.C.:U.S. Patent and Trademark Office.
- Renshaw PF (2011). Compounds for the treatment of psychiatric or substance abuse disorders. U.S. Patent No. 8,030,294. Washington, D.C.:U.S. Patent and Trademark Office.
- Rohan ML, Renshaw PF, Parrow A (2011). Magnetic filed treatment techniques. U.S. Patent No. 8,047,979. Washington, D.C.:U.S. Patent and Trademark Office.
- Lukas SE, Renshaw PF (2011). Compounds for the treatment of marihuana dependence, withdrawal, and usage. U.S. Patent No. 7,947,611. Washington, D.C.:U.S. Patent and Trademark Office.
- Lukas SE, Renshaw PF (2010). Compounds for the treatment of marijuana dependence, withdrawal, and usage. U.S. Patent No. 7,947,661. Washington, D.C.:U.S. Patent and Trademark Office.
- Rohan ML, Parow A, Renshaw PF (2007). Magnetic field stimulation techniques. U.S. Patent No. 7,282,021. Washington, D.C.:U.S. Patent and Trademark Office.
- Rohan ML, Parow A, Renshaw PF (2006). Magnetic field stimulation techniques. U.S. Patent No. 7,033,312. Washington, D.C.:U.S. Patent and Trademark Office.
- Rohan ML, Renshaw PF, Parow A (2006). Magnetic field treatment techniques. U.S. Patent No. 8,047,979. Washington, D.C.:U.S. Patent and Trademark Office.
- Anderson CM, Lowen SB, Renshaw PF, Teicher MH, Maas LC (2005). Method for providing optimal drug dosage. U.S. Patent No. 6,898,455. Washington, D.C.:U.S. Patent and Trademark Office.
- Renshaw PF (2004). Pyrimidines, such as uridine, in treatments for patients with bipolar disorder. U.S. Patent No. 6,898,455. Washington, D.C.:U.S. Patent and Trademark Office.
- Ke Y, Renshaw PF, Cohen BM (2003). Two-dimensional MR spectroscopy techniques. U.S. Patent No. 6,617,169. Washington, D.C.:U.S. Patent and Trademark Office.
- Renshaw PF, Parow AM, Rohan M (2003). Magnetic field stimulation techniques. U.S. Patent No. 6,572.528. Washington, D.C.:U.S. Patent and Trademark Office.
- Renshaw PF (2003). Method and apparatus for detecting mental illness. U.S. Patent No. 6 ,400,978. Washington, D.C.:U.S. Patent and Trademark Office.
- Renshaw PF, Cowan RL, Frederick B (2003). Method for assessing cortical response to blue light. U.S. Patent No. 6,630.127. Washington, D.C.:U.S. Patent and Trademark Office.
- Renshaw PF (2000). Treatment of mental conditions including depression. U.S. Patent No. 6,258,794. Washington, D.C.:U.S. Patent and Trademark Office.
- Renshaw PF, Lukas SE (2000). Cytidine-containing and cytosine-containing compounds as a treatment for stimulant exposure. CIP 6,103,703. (Applications pending for use in depression, alcohol abuse/dependence, and ADHD.). U.S. Patent No. 5,958,896. Washington, D.C.:U.S. Patent and Trademark Office.
- Frederick B, Wald L, Renshaw PF (2000). Phased array echo-planer imaging system for fMRI. U.S. Patent No. 6,104,943. Washington, D.C.:U.S. Patent and Trademark Office.
- Renshaw PF, Lukas SE (2000). Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure. U.S. Patent No. 6,103,703. Washington, D.C.:U.S. Patent and Trademark Office.
- Maas LC, Frederick B, Renshaw PF (1998). Decoupled automated rotational and translational registration for functional MRI time series data: the DART registration algorithm. U.S. Patent No. 5,850,486. Washington, D.C.:U.S. Patent and Trademark Office.